Nov.07 — Alan Yu, vice president and chief operating officer at CK Life Sciences, discusses the drug advance that’s causing its share price to surge, where he is in the approval process, when the drug will be available to the public, how it’s different from others in the market and their partnerships with other drug makers. He speaks exclusively on “Bloomberg Markets: Asia.”
